Key result
Add-on low-dose vericiguat improves functional status from NYHA class III to I in decompensated HF.
Why the study?
The effect of vericiguat on patients with HFrEF receiving SGLT2 inhibitors remains uncertain, especially in those intolerant to standard foundational therapy doses.
Does low-dose vericiguat improve clinical parameters in a patient with decompensated HFrEF intolerant to standard foundational therapy?
Case Report (n=1)
Does low-dose vericiguat improve clinical parameters in a patient with decompensated HFrEF intolerant to standard foundational therapy?
Low-dose vericiguat may offer clinical benefits, including improved cardiac and renal function, in HFrEF patients intolerant to standard foundational therapies.
Case experience with vericiguat plus SGLT2i in HFrEF is hypothesis-generating; dedicated trials needed to clarify combined use.
Vericiguat has emerged as a promising add-on therapy for decompensated heart failure with reduced ejection fraction (HFrEF) patients requiring hospitalization or IV diuretic administration. In the VICTORIA trial (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), vericiguat was demonstrated to significantly reduce mortality and hospitalization rates. However, the effect of vericiguat on patients receiving SGLT2 inhibitors remains uncertain. In this report, we present a complicated case of dilated heart failure receiving low doses of foundational therapy due to a patient's intolerance but still experiencing recurrent hospital readmissions. Following six months of low-dose vericiguat as an add-on therapy, the patient exhibited important improvements in various clinical parameters, including cardiac and renal function. Nonetheless, further investigation is crucial to substantiate the additional benefits of combination therapy. These findings provide further evidence for the potential benefits of vericiguat when treating HFrEF.
No takes yet. Share an insight, caveat, or question.
Speranza-Sánchez et al. (2023) conducted a case report in Decompensated heart failure with reduced ejection fraction (n=1). Vericiguat was evaluated on Clinical parameters including NYHA class, pro-BNP levels, renal function, and hospitalization rates. Six months of low-dose vericiguat add-on therapy in a 72-year-old male with decompensated heart failure improved NYHA class from III to I, reduced pro-BNP, and prevented hospitalizations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: